PainReform(PRFX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRFX PainReform

Post-Mkt 01-12 18:27:20 EST

0.8028

-0.0472

-5.55%

盘后0.8400

+0.0372+4.63%

17:47 EST

High0.9242	Low0.7800	Vol682.31K
Open0.8400	D1 Closing0.8500	Amplitude16.96%
Mkt Cap3.14M	Tradable Cap3.00M	Total Shares3.92M
T/O578.57K	T/O Rate18.26%	Tradable Shares3.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRFX","market":"US","secType":"STK","nameCN":"PainReform","latestPrice":0.8028,"timestamp":1768251600000,"preClose":0.85,"halted":0,"volume":682307,"hourTrading":{"tag":"盘后","latestPrice":0.84,"preClose":0.8028,"latestTime":"17:47 EST","volume":23533,"amount":19888.09694292,"timestamp":1768258020343},"delay":0,"floatShares":3736600,"shares":3915299,"eps":-1.0435876,"marketStatus":"Post-Mkt","change":-0.0472,"latestTime":"01-12 18:27:20 EST","open":0.84,"high":0.9242,"low":0.78,"amount":578570.79042592,"amplitude":0.169647,"askPrice":0.87,"askSize":46,"bidPrice":0.8,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.0435876,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768266000000},"marketStatusCode":4,"adr":0,"listingDate":1598932800000,"exchange":"NASDAQ","adjPreClose":0.85,"preHourTrading":{"tag":"盘前","latestPrice":0.8386,"preClose":0.85,"latestTime":"09:29 EST","volume":69695,"amount":58311.3602055,"timestamp":1768228189981},"postHourTrading":{"tag":"盘后","latestPrice":0.84,"preClose":0.8028,"latestTime":"17:47 EST","volume":23533,"amount":19888.09694292,"timestamp":1768258020343},"volumeRatio":4.089211},"requestUrl":"/m/hq/s/PRFX/wiki","defaultTab":"wiki","newsList":[{"id":"2602462055","title":"PainReform Reports Positive Phase I Safety Data for OcuRing-K Ocular Drug Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2602462055","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602462055?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:37","pubTimestamp":1768228670,"startTime":"0","endTime":"0","summary":"The latest update is out from PainReform ( ($PRFX) ). On January 12, 2026, PainReform and its majority-owned subsidiary LayerBio reported that thei...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/painreform-reports-positive-phase-i-safety-data-for-ocuring-k-ocular-drug-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/painreform-reports-positive-phase-i-safety-data-for-ocuring-k-ocular-drug-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PRFX"],"gpt_icon":0},{"id":"2602754308","title":"PainReform Ltd - Announces Safety Data for Ocuring™-K Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2602754308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602754308?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:04","pubTimestamp":1768226661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PRFX"],"gpt_icon":0},{"id":"2602543036","title":"PainReform Ltd - Preclinical Studies Show Favorable Tolerability for Ocuring™-K","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543036?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:04","pubTimestamp":1768226661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0QP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRFX","BK4007"],"gpt_icon":0},{"id":"2602543742","title":"PainReform’s OcuRing-K Platform Shows Favorable Safety in Phase I Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543742","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543742?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:02","pubTimestamp":1768226537,"startTime":"0","endTime":"0","summary":"PainReform Ltd. and its majority-owned subsidiary, LayerBio, Inc., have announced safety data from the development program of the OcuRing-K drop-less, sustained-release ocular drug delivery platform intended for use in cataract surgery. The program included a series of preclinical rabbit studies and a Phase I clinical study in patients undergoing cataract surgery. The results from these studies, which have already been presented, demonstrated a favorable safety profile for the platform, supporting its continued advancement toward later-stage clinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PainReform Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL1JRPVB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014013.SGD","PRFX","IE00B3QW5Z07.USD","NDAQ","BK4007","LU0314104364.USD","IE00B64PRP62.GBP","BK4588","SG9999014039.USD","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2601314843","title":"PainReform Ltd. held shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2601314843","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601314843?lang=en_us&edition=fundamental","pubTime":"2026-01-07 05:16","pubTimestamp":1767734168,"startTime":"0","endTime":"0","summary":"PainReform Ltd. held its Adjourned Annual General Meeting of Shareholders on January 6, 2026. All six proposals brought before the shareholders at the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PainReform Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL6fFPsT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PRFX"],"gpt_icon":0},{"id":"2601882839","title":"DeepSolar Launches Smart TDD to Boost Global Solar Asset Due Diligence","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882839","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601882839?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:00","pubTimestamp":1767621613,"startTime":"0","endTime":"0","summary":"PainReform Ltd.'s DeepSolar Launches Smart TDD, Revolutionizing Global Solar Asset Due Diligence. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PainReform Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL7qcZ3S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","PRFX","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","LU0314104364.USD","BK4007","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2590158705","title":"PainReform Confirms LayerBio Ocular Platform Can Deliver Multiple Drugs in Sustained-Release Form","url":"https://stock-news.laohu8.com/highlight/detail?id=2590158705","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590158705?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373408,"startTime":"0","endTime":"0","summary":"PainReform Ltd. has announced the completion of a research and development assessment of LayerBio's proprietary drop-less, sustained-release ocular drug-delivery platform. The results confirm that the platform's sustained-release polymer matrix can incorporate a variety of drug entities. This finding supports the platform's long-term potential to improve pharmacological efficiency and simplify postoperative care for cataract patients by reducing or eliminating the need for medicated eye drops. The results were announced by the company and have not been specified as already presented or scheduled to be presented at a future event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PainReform Ltd. published the original content used to gener","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL1GC1qT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4112","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","BK4007","PRFX","SG9999014005.SGD","BK4588","BK4585","SG9999014039.USD"],"gpt_icon":0},{"id":"2588141059","title":"BRIEF-Painreform Commences Development For Ocuring™-K Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588141059","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588141059?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:19","pubTimestamp":1764685168,"startTime":"0","endTime":"0","summary":"BRIEF-Painreform Commences Development For Ocuring-K Phase II TrialDec 2 (Reuters) - PainReform Ltd PRFX.O:PAINREFORM COMMENCES DEVELOPMENT FOR OCURING-K PHASE II TRIAL, LAYERBIO’S DROP-LESS SUSTAINED","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA8LJ8X4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRFX","BK4007"],"gpt_icon":0},{"id":"2588596050","title":"PainReform Advances Drop-Less OcuRing-K Therapy Toward Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588596050","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588596050?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:15","pubTimestamp":1764684911,"startTime":"0","endTime":"0","summary":"PainReform Ltd. has announced the commencement of its development plan for OcuRing-K, an innovative, drop-less, sustained-release ocular therapy designed to deliver controlled ketorolac following cataract surgery. The company, in collaboration with LayerBio, is advancing OcuRing-K toward a Phase II clinical trial in the United States. The initial target indication is for post-cataract pain and inflammation, with the goal of providing consistent control with significantly lower drug exposure than traditional eye drops. The research and development efforts are ongoing, and future updates will be provided as the program progresses. No specific scientific research results have been presented yet; the results will be generated and shared following the next stages of clinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3fn5n6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","BK4007","BK4112","BK4588","PRFX","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2588305963","title":"PainReform Commences Development for Ocuring™-K Phase Ii Trial, Layerbio’s Drop-Less Sustained-Release Ocular Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588305963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588305963?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:15","pubTimestamp":1764684900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA8LJ8X4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PRFX"],"gpt_icon":0},{"id":"2586940122","title":"PainReform Ltd. Announces December 2025 Shareholders Meeting with Key Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2586940122","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586940122?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:54","pubTimestamp":1764107682,"startTime":"0","endTime":"0","summary":"The latest announcement is out from PainReform ( ($PRFX) ). On November 25, 2025, PainReform Ltd. announced its upcoming Annual General Meeting of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/painreform-ltd-announces-december-2025-shareholders-meeting-with-key-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/painreform-ltd-announces-december-2025-shareholders-meeting-with-key-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRFX","BK4007"],"gpt_icon":0},{"id":"2586409152","title":"PainReform Ltd. Announces Date for Upcoming Annual General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2586409152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586409152?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:16","pubTimestamp":1764105392,"startTime":"0","endTime":"0","summary":"PainReform Ltd. has announced that it will hold its Annual General Meeting of Shareholders on December 30, 2025, at the offices of its attorneys in Tel Aviv, Israel. During the meeting, shareholders will be asked to approve the re-election of Dr. Ehud Geller to the Board of Directors as a Class I director. They will also vote on a proposal to change the company's name from \"PainReform Ltd.\" to \"PRF Ltd.\" and amend the company's articles of association accordingly, subject to regulatory approval. Additionally, shareholders will consider the approval of a grant of options to Asaf Shavit, a member of the Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PainReform Ltd. published the original content used to generate this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL945FMQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRFX","BK4007"],"gpt_icon":0},{"id":"2582773653","title":"PainReform’s DeepSolar advances development of AI-driven reporting engine","url":"https://stock-news.laohu8.com/highlight/detail?id=2582773653","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582773653?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:10","pubTimestamp":1762956639,"startTime":"0","endTime":"0","summary":"PainReform (PRFX) announced that DeepSolar has advanced the development of its proprietary automated reporting engine, designed to transform how so...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/painreforms-deepsolar-advances-development-of-ai-driven-reporting-engine-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/painreforms-deepsolar-advances-development-of-ai-driven-reporting-engine-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRFX"],"gpt_icon":0},{"id":"2582372511","title":"DeepSolar Advances AI-Driven Reporting Engine for Solar Asset Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372511","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372511?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:00","pubTimestamp":1762956032,"startTime":"0","endTime":"0","summary":"PainReform Ltd.'s solar energy business unit, DeepSolar, is advancing development of its proprietary AI-driven automated reporting engine for solar-asset analysis. The new platform aims to automate data consolidation and reporting, providing tailored, insight-rich performance reports for executive management, investors, and asset owners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PainReform Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLk0VS0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","LU0314104364.USD","PRFX","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2581775944","title":"PainReform’s DeepSolar Advances with NVIDIA Connect and Pilot Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2581775944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581775944?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:17","pubTimestamp":1762352267,"startTime":"0","endTime":"0","summary":"PainReform ( ($PRFX) ) has provided an update. On November 5, 2025, PainReform Ltd. announced that its solar energy unit, DeepSolar, was featured i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/painreforms-deepsolar-advances-with-nvidia-connect-and-pilot-projects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/painreforms-deepsolar-advances-with-nvidia-connect-and-pilot-projects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRFX"],"gpt_icon":0},{"id":"2581778488","title":"BRIEF-PainReform’s DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link’s “Watchlist Interview” and Announces Progress Toward Pilot Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2581778488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581778488?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:37","pubTimestamp":1762349873,"startTime":"0","endTime":"0","summary":"BRIEF-PainReform’s DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link’s “Watchlist Interview” and Announces Progress Toward Pilot ProjectsNov 5 (R","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA1PDPCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVD","LU0348723411.USD","LU0077335932.USD","LU1244550221.USD","LU2023250330.USD","PRFX","LU1804176565.USD","NVDU","IE00BZ1G4Q59.USD","LU1066051225.USD","NVDX","LU2242650005.HKD","LU1633808545.USD","LU0353189680.USD","LU2452424414.USD","NVD2.UK","NVDS.UK","LU1778281490.HKD","SNVD.UK","LU1721428933.USD","NVDY","LU0251132253.USD","NVIW.SI","NVDD","LU2168564149.EUR","LU2506951792.HKD","IE0009356076.USD","NVDS","SG9999014542.SGD","LU0057025933.USD","IE00BKPKM429.USD","LU0158827781.USD","LU0882574139.USD","SG9999015986.USD","LU0203202063.USD","LU0476273544.USD","LU1720051017.SGD","LU1923622614.USD","LU2125909759.SGD","LU0964807845.USD","NVD3.UK","LU2413666426.HKD","LU0266013472.USD","LU1917777945.USD","LU1699723380.USD","2NVD.UK","3NVD.UK","LU0203201768.USD"],"gpt_icon":1},{"id":"2581786637","title":"PainReform’s Deepsolar, Developing “Deepsolar Predict” Within the Nvidia Connect Program, Featured in the Market Link’s “Watchlist Interview” and Announces Progress Toward Pilot Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2581786637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581786637?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:30","pubTimestamp":1762349401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA1PDPCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVDS","2NVD.UK","LU2097344431.USD","NVDX","LU0048584097.USD","LU1548497426.USD","NVIW.SI","LU2065171402.SGD","SG9999015952.SGD","NVDL","LU1992135472.HKD","LU2097344357.USD","LU2322448791.USD","LU1435385759.SGD","NVDS.UK","LU2237438978.USD","LU1821325948.USD","LU2087625088.SGD","LU0256863902.USD","LU1429558221.USD","NVDD","IE00BJTD4V19.USD","LU1815333072.USD","IE00BDRTCR15.USD","NVD","BK4533","LU0310800379.SGD","LU2413666426.HKD","NVD3.UK","NVDY","LU1934455863.HKD","LU2361044949.HKD","LU1119994496.HKD","LU2125909247.SGD","LU1815336760.USD","IE00B1XK9C88.USD","3NVD.UK","LU1323610961.USD","LU0072462426.USD","NVDA","LU1066051498.USD","LU2361044865.SGD","LU2746668974.SGD","NVDU","NVD2.UK","SG9999014575.USD","PRFX","SNVD.UK","SGXZ23171101.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2572553728","title":"BRIEF-Painreform Provides Business Update For The Six Months Ended June 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2572553728","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572553728?lang=en_us&edition=fundamental","pubTime":"2025-10-01 22:28","pubTimestamp":1759328924,"startTime":"0","endTime":"0","summary":"BRIEF-Painreform Provides Business Update For The Six Months Ended June 30, 2025Oct 1 (Reuters) - PainReform Ltd PRFX.O:PAINREFORM PROVIDES BUSINESS UPDATE FOR THE SIX MONTHS ENDED JUNE 30, 2025Source text: ID:nGNX2RDnkBFurther company coverage: PRFX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nTUA40BKMX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PRFX"],"gpt_icon":0},{"id":"2572532708","title":"PainReform Announces H1 2025 Financial Results and Board Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2572532708","media":"TIPRANKS","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572532708?lang=en_us&edition=fundamental","pubTime":"2025-10-01 21:59","pubTimestamp":1759327153,"startTime":"0","endTime":"0","summary":"An update from PainReform ( ($PRFX) ) is now available. On October 1, 2025, PainReform Ltd. announced its financial results for the first half of t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/painreform-announces-h1-2025-financial-results-and-board-change?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/painreform-announces-h1-2025-financial-results-and-board-change?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PRFX"],"gpt_icon":0},{"id":"2572246534","title":"PainReform Ltd. Reports Reduced Net Loss and Maintains Positive Working Capital for First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2572246534","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572246534?lang=en_us&edition=fundamental","pubTime":"2025-10-01 21:28","pubTimestamp":1759325281,"startTime":"0","endTime":"0","summary":"For the six months ended June 30, 2025, general and administrative expenses were $1.9 million, compared to $1.5 million for the six months ended June 30, 2024. The increase was mainly attributable to higher legal costs and share-based compensation expenses. Research and development expenses were $0.3 million for the six months ended June 30, 2025, compared to $11.4 million for the six months ended June 30, 2024. The decrease was primarily due to the completion of the Phase 3 clinical trial evaluating PRF-110 in 2024. Financial income, net, was $52,000 for the six months ended June 30, 2025, compared to $92,000 for the six months ended June 30, 2024. The decrease was primarily due to lower cash balances in 2025. Net loss for the six months ended June 30, 2025, was $2.3 million, compared to $12.8 million for the six months ended June 30, 2024. As of June 30, 2025, cash and cash equivalents  were $3.5 million, and working capital was $1.5 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL43HLqD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","LU0314104364.USD","PRFX","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.painreform.com","stockEarnings":[{"period":"1week","weight":0.2162},{"period":"1month","weight":-0.1196},{"period":"3month","weight":-0.3487},{"period":"6month","weight":-0.3885},{"period":"1year","weight":-0.7319},{"period":"ytd","weight":0.3244}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.005254},{"month":2,"riseRate":0.6,"avgChangeRate":0.112661},{"month":3,"riseRate":0.4,"avgChangeRate":-0.068689},{"month":4,"riseRate":0.2,"avgChangeRate":-0.216174},{"month":5,"riseRate":0,"avgChangeRate":-0.142442},{"month":6,"riseRate":0.4,"avgChangeRate":-0.0782},{"month":7,"riseRate":0.4,"avgChangeRate":-0.022654},{"month":8,"riseRate":0.4,"avgChangeRate":-0.15911},{"month":9,"riseRate":0.2,"avgChangeRate":-0.17317},{"month":10,"riseRate":0,"avgChangeRate":-0.160968},{"month":11,"riseRate":0.5,"avgChangeRate":-0.020834},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.071991}],"exchange":"NASDAQ","name":"PainReform","nameEN":"PainReform"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PainReform(PRFX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PainReform(PRFX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PainReform,PRFX,PainReform股票,PainReform股票老虎,PainReform股票老虎国际,PainReform行情,PainReform股票行情,PainReform股价,PainReform股市,PainReform股票价格,PainReform股票交易,PainReform股票购买,PainReform股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PainReform(PRFX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PainReform(PRFX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}